India specialty chemicals recovery and outlook

Now the signs are turning. Listed companies’ revenue rebounded in FY26, led by CRAMS, CSM and CDMO businesses, which have posted the strongest revenue growth over FY20-FY26. Margins are recovering too, inventories are normalizing and Q1FY27 brought broader revenue growth plus sequential margin improvement. In other words, the sector is no longer just hoping for relief — it is showing it in the numbers.

That matters economically because specialty chemicals sit at the intersection of manufacturing, exports and higher-value industrial production. When these companies recover, it usually means downstream demand is firming, operating leverage is kicking in and pricing discipline is coming back. For India, it also reinforces the case that the country can move further up the global chemicals value chain rather than competing only on commodity volumes.

For investors, the story is less about a quick rebound and more about whether this recovery can compound. Equirus says the market is projected to expand from $36 billion in 2025 to $61 billion by 2030, which points to a long runway if companies can keep capital discipline intact. That is the key lesson here: the best specialty chemical names are not the ones that spend the most, but the ones that convert demand recovery into sustained free cash flow and returns on capital.

There are still risks. The sector has already seen how quickly excess capacity can crush margins, and a weak global industrial cycle could slow the normalization. But the broad message is clearer now: the worst of the de-rating phase may be over, and the winners are likely to be the companies with export reach, CDMO-linked growth and the pricing power to protect margins when the cycle inevitably cools again.

For long-term investors, that makes India’s specialty chemicals space worth watching closely. This is the kind of recovery that can be easy to miss while it is happening and much harder to buy once the market has already recognized it.